Thrombosis in Nephrotic Syndrome

被引:72
作者
Barbano, Biagio [1 ]
Gigante, Antonietta [1 ]
Amoroso, Antonio [1 ]
Cianci, Rosario [1 ]
机构
[1] Univ Roma La Sapienza, Dept Clin Med, Nephrol Unit, I-00185 Rome, Italy
关键词
arterial thrombosis; deep vein thrombosis; nephrotic syndrome; proteinuria; renal vein thrombosis; pulmonary embolism; RENAL-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; MEMBRANOUS NEPHROPATHY; COAGULATION-FACTORS; PULMONARY-EMBOLISM; RISK-FACTORS; PROPHYLACTIC ANTICOAGULATION; PLATELET HYPERAGGREGABILITY; ALBUMIN METABOLISM; CLINICAL SPECTRUM;
D O I
10.1055/s-0033-1343887
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nephrotic syndrome (NS) is characterized by heavy proteinuria, edema, hypoalbuminemia, and hyperlipidemia and the most frequent causes are glomerular diseases. An uncommon presentation is iatrogenic NS, an adverse effect of some drugs administration. In the clinical course of NS, a typical feature is dysregulated coagulation state, promoted by the breakdown of permselectivity barrier of the glomerular capillary wall, resulting in the leakage of high-molecular-mass proteins, at least the size of albumin. This hypercoagulable condition is supported by several factors, such as abnormalities in platelet activation and an imbalance between anticoagulation/antithrombosis and procoagulant/prothrombotic mechanisms. Thus, NS and the risk of developing thromboses are strictly related. Thrombotic events affect the venous system rather than arterial vessels with different features and frequencies. Deep venous system of the lower extremities and renal veins are the most frequent source of pulmonary embolism, the most dangerous NS complication. Prophylactic anticoagulation and thrombosis treatment are not clearly established because large randomized trials and guidelines are lacking. The management of NS and the decision of when and how to anticoagulate the patient represent a teamwork challenge for physicians.
引用
收藏
页码:469 / 476
页数:8
相关论文
共 85 条
[51]  
Nachman PH, 2007, BRENNER RECTORS KIDN, P987
[52]   Medical progress - The nephrotic syndrome [J].
Orth, SR ;
Ritz, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (17) :1202-1211
[53]   Hypercoagulability risk factors in children with minimal change disease and the protective role of protein-C activity [J].
Öskayin N. ;
Mir S. ;
Kavakli K. .
International Urology and Nephrology, 2004, 36 (4) :599-603
[54]   Statins and venous thromboembolism: a novel effect of statins? [J].
Paraskevas, Kosmas I. ;
Bessias, Nikolaos ;
Perdikides, Theodossios P. ;
Mikhailidis, Dimitri P. .
CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (07) :1807-1809
[55]   Bisphosphonate nephrotoxicity [J].
Perazella, Mark A. ;
Markowitz, Glen S. .
KIDNEY INTERNATIONAL, 2008, 74 (11) :1385-1393
[56]  
Ponticelli C, 2009, TREATMENT PRIMARY GL, P21
[57]   New Oral Anticoagulants A Review of the Literature with Particular Emphasis on Patients with Impaired Renal Function [J].
Poulsen, Birgitte Klindt ;
Grove, Erik Lerkevang ;
Husted, Steen Elkjaer .
DRUGS, 2012, 72 (13) :1739-1753
[58]   THROMBOSIS AND HEMOSTASIS IN RENAL-DISEASE [J].
RABELINK, TJ ;
ZWAGINGA, JJ ;
KOOMANS, HA ;
SIXMA, JJ .
KIDNEY INTERNATIONAL, 1994, 46 (02) :287-296
[59]  
Radhakrishnan J., 2012, RENAL VEIN THROMBOSI
[60]   Venous Thromboembolism and Membranous Nephropathy: So What's New? [J].
Radhakrishnan, Jai .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 7 (01) :3-4